StartCell

The purpose of this Vinnova-funded project is to facilitate the development of high-quality, commercially available induced pluripotent stem cells (iPSCs) for the derivation of new cell therapies. The project’s work packages address this by tackling both technical and commercial challenges such as IP, licensing, health economics and market access, upscaling, and new methods for quality assurance.

StartCell is led by the University of Lund. Other partners in the project are CCRM Nordic, Skövde University, Karolinska Institutet, KTH, LU Innovation, Region Skåne, Karolinska University Hospital and Takara Bio Europe. IHE is leading work package focusing on understanding the cost of the production process and the implications on acceptable value based price for these kinds of therapies.